Corporate-speak at its best: "We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors." So reads a statement from Turing Pharmaceuticals Friday. Martin, of course, is Martin Shkreli, whose name now usually comes with words like "infamous," "notorious," or "reviled pharma bro." And his "future endeavors" include fending off charges of securities fraud filed against him on Thursday. The 32-year-old resigned on Friday as CEO of Turing, the company he made Internet-famous by jacking up the price of a life-saving drug by 5,000%, reports USA Today.
The new charges are unrelated to his tenure at Turing, which began in late 2014. Shkreli remains CEO of KaloBios Pharmaceuticals, though authorities are investigating his takeover of that company last month, reports the Wall Street Journal. (It happened under unusual circumstances.) Click for a roundup of other Shkreli-related stories, including the fate of his famous new album from the Wu-Tang Clan. (Read more Martin Shkreli stories.)